WO2001068076A8 - D-enantiomer of dfmo and methods of use thereof for treating cancer - Google Patents

D-enantiomer of dfmo and methods of use thereof for treating cancer

Info

Publication number
WO2001068076A8
WO2001068076A8 PCT/US2001/007607 US0107607W WO0168076A8 WO 2001068076 A8 WO2001068076 A8 WO 2001068076A8 US 0107607 W US0107607 W US 0107607W WO 0168076 A8 WO0168076 A8 WO 0168076A8
Authority
WO
WIPO (PCT)
Prior art keywords
dfmo
enantiomer
methods
treating cancer
analog
Prior art date
Application number
PCT/US2001/007607
Other languages
French (fr)
Other versions
WO2001068076A3 (en
WO2001068076A2 (en
Inventor
Corey Levenson
Ze Ev Shaked
Original Assignee
Ilex Oncology Inc
Corey Levenson
Ze Ev Shaked
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/801,197 external-priority patent/US6602910B2/en
Application filed by Ilex Oncology Inc, Corey Levenson, Ze Ev Shaked filed Critical Ilex Oncology Inc
Priority to CA002402122A priority Critical patent/CA2402122A1/en
Priority to EP01914781A priority patent/EP1261326A1/en
Priority to JP2001566640A priority patent/JP2004504271A/en
Priority to AU40132/01A priority patent/AU4013201A/en
Publication of WO2001068076A2 publication Critical patent/WO2001068076A2/en
Publication of WO2001068076A3 publication Critical patent/WO2001068076A3/en
Publication of WO2001068076A8 publication Critical patent/WO2001068076A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention concerns a method for preventing and/or treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine (D-DFMO) or an analog of D-DFMO to the patient. D-DFMO or an analog thereof is administered at a dose of about 0.05 to about 20.0 gm/M2/day. D-DFMO or an analog thereof may be administered more than once for the treatment and/or prevention of cancer. Methods of administration as well as compositions and formulations of substantially purified D-DFMO and analogs of D-DFMO are described.
PCT/US2001/007607 2000-03-07 2001-03-07 D-enantiomer of dfmo and methods of use thereof for treating cancer WO2001068076A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002402122A CA2402122A1 (en) 2000-03-07 2001-03-07 D-enantiomer of dfmo and methods of use therefor
EP01914781A EP1261326A1 (en) 2000-03-07 2001-03-07 D-enantiomer of dfmo and methods of use therefor for treating cancer
JP2001566640A JP2004504271A (en) 2000-03-07 2001-03-07 D-enantiomers of DFMO and methods of using the same to treat cancer
AU40132/01A AU4013201A (en) 2000-03-07 2001-03-07 D-enantiomer of dfmo and methods of use therefor

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18741100P 2000-03-07 2000-03-07
US60/187,441 2000-03-07
US21586600P 2000-07-01 2000-07-01
US60/215,866 2000-07-01
US09/801,197 2001-03-06
US09/801,197 US6602910B2 (en) 2000-03-07 2001-03-06 D-enantiomer of DFMO and methods of use therefor

Publications (3)

Publication Number Publication Date
WO2001068076A2 WO2001068076A2 (en) 2001-09-20
WO2001068076A3 WO2001068076A3 (en) 2003-03-06
WO2001068076A8 true WO2001068076A8 (en) 2003-06-19

Family

ID=27392244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/007607 WO2001068076A2 (en) 2000-03-07 2001-03-07 D-enantiomer of dfmo and methods of use thereof for treating cancer

Country Status (1)

Country Link
WO (1) WO2001068076A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002343609B2 (en) * 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
US7015349B2 (en) 2003-03-26 2006-03-21 The Gillette Company Reduction of hair growth
US8329636B2 (en) 2009-05-14 2012-12-11 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment, based on ODC1 genotype
LT2912193T (en) 2012-10-29 2018-12-27 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
US10655183B2 (en) 2014-06-18 2020-05-19 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment based on ODC1 genotype
AU2016343851B2 (en) 2015-10-30 2022-04-07 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
CN117530943A (en) 2016-10-06 2024-02-09 奥巴斯治疗股份有限公司 Formulations for administration of efluromithine
CA3139162A1 (en) 2019-05-17 2020-11-26 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4751597A (en) * 1996-10-04 1998-04-24 Ilex Oncology, Inc. Dfmo and taxol for the treatment or prevention of breast cancer
EP0886519A1 (en) * 1996-11-01 1998-12-30 Ilex Oncology, Inc. Sustained release formulation containing dfmo
AU5526898A (en) * 1996-12-13 1998-07-03 Ilex Oncology, Inc. Isomeric pharmaceutical formulation containing dfmo for the treatment of cancer
AU754864B2 (en) * 1998-03-28 2002-11-28 Arizona Board Of Regents On Behalf Of The University Of Arizona, The DFMO and sulindac combination in cancer chemoprevention
JP2002544229A (en) * 1999-05-17 2002-12-24 アイレックス オンコロジー， インコーポレイテッド DFMO and celecoxib combined for chemoprevention and treatment of cancer

Also Published As

Publication number Publication date
WO2001068076A3 (en) 2003-03-06
WO2001068076A2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
HUP0100437A2 (en) Therapeutic formulation for administering tolterodine with controlled release
CA2427227A1 (en) Lactam compound
HUP0203198A2 (en) Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
RU98111594A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING FLURBIPROFEN
CA2375908A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
FI935847A (en) L-DOPA ester compositions
MXPA04003866A (en) Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder.
CA2070685C (en) Method for treating painful, inflammatory or allergic disorders
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
CA2459470A1 (en) Pharmaceutical composition comprising gabapentin or an analogue thereof and an .alpha.-aminoamide and its analgesic use
UA92498C2 (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
KR970061244A (en) Pharmaceutical composition for treating dementia
WO2001068076A8 (en) D-enantiomer of dfmo and methods of use thereof for treating cancer
MXPA05005781A (en) Combination of ibuprofen and oxycodone for acute pain relief.
ES2136167T3 (en) IDEBENONE COMPOSITIONS TO TREAT ALZHEIMER'S DISEASE.
HK1087039A1 (en) Use of biphosphonate in preparing medical kit and a kit used for increasing bone mass
WO2002064214A3 (en) Anti cancer combination of substituted pyrroles and paclitaxel
EP0744176A3 (en) Methods for inhibiting bone loss
CA2350396A1 (en) A composition useful to treat periodontal disease
GEP20032969B (en) Sertraline Oral Concentrate
RU2003113210A (en) TREATMENT OF CANCER DISEASES
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
CA2403674A1 (en) The use of t3 for treating congestive heart failure

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 40132/01

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 566640

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001914781

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2402122

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 018091075

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001914781

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 38/2001 UNDER (30) AND (63) REPLACE "NOT FURNISHED" BY "09/801,197"

WWW Wipo information: withdrawn in national office

Ref document number: 2001914781

Country of ref document: EP